You are on page 1of 4

Ethics and CSR

GROUP ASSIGNMENT – PART B

Submitted to:
Prof. Kajari Mukherjee

Submitted by:
Group 3
Section - F
Assignment B: 30% Weightage (Word limit 1000, Font: Times New
Roman, Alignment: Justified)

The recent advancements in the field of bio-technology are full of exciting
commercial implications.
In many cases, one can already see the corporate sector willing to go to
great lengths to explore the promise that the bio-technological
breakthroughs are providing and to turn them to commercial
advantages. As an industry, the bio-technology industry is still in its
inception. However, in many of these cases like, human genome project,
stem cell research, surrogacy issues, there have been debates revolving
around the ethical aspects involved in this industry. Given this fact, what
are the various ethical issues involved in commercialization of the bio-
technology advancements. Please debate the issues thoroughly within
your group.
Each group is required to illustrate its standpoint by examining its views
in the context of one of the following:

a) Human Genome Project, b) GMOs, c) Stem cell Research, and d)
Surrogacy

There is a huge open level headed discussion about how the potential dangers connected
with biotechnology strategies and bio-industry items ought to be evaluated and about
whether and how bioethics ought to impact open arrangement. A general structure for
controlling open strategy talk is rising yet is not completely created. Bunches see hazards
distinctively relying upon their way of life, logical foundation, view of government, and
different elements. Master feeling underpins a scope of positions. Profoundly and
genuinely held yet frequently clashing convictions and values about nature, creatures,
and the group great vitalize the civil argument. The outcome is that biotechnology issues
are frequently exceedingly quarrelsome and bantered on both logical and moral grounds.
Two contemporary cases are:

• Do human social advantages, for example, living a more drawn out and driving
more profitable life because of biotechnology exceed the mischief that a creature or
gatherings of creatures must understanding to deliver those advantages.

• Should an insurance agency require data around an individual's hereditary legacy
as a state of qualification for medical coverage?

Biotechnology's dangers are now and again simply speculative. Without research and
clinical trials, dangers can't be completely evaluated. However, assumed and moral issues
are critical on the grounds that biotechnology influences human practices and financial
divisions, as well as restorative practices and the relationship between humankind,
creatures and the earth. In Paul Thompson's view,
Biotechnology is not just another kind of mechanical or concoction creation went for
improving the world for us. In this occurrence, we are not just reshaping matter, but
rather are outfitting life. By controlling life and characteristic development, we are taking
the procedure that formed our reality and that of each other living being on the planet and
rebuilding it for our own particular advantage.

Debate relating to Ethics

In May 1995, an extensive coalition of religious pioneers - Catholic clerics, Protestant
and Jewish pioneers and gatherings of Muslims, Hindus and Buddhists - reported their
resistance to licenses on human and creature life. The coalition did not contradict
hereditary building or biotechnology, yet rather protecting human qualities or living
beings. It battles that such licenses damage the holiness of human life and diminish the
"diagram of advancement" to an attractive ware. The gathering contends that life is a
blessing from God that ought to be esteemed and supported. To lessen life to a ware is to
transform it into an item that can be claimed and controlled for benefit alone, as indicated
by the group.

The people, creatures, microorganisms and plants including life on the earth are a piece
of the characteristic world into which we were altogether conceived. The change of these
life frames, their particles or parts into corporate property all through patent imposing
business models is counter to the interests of the people groups of the world.

No individual, foundation, or organization ought to have the capacity to claim
responsibility for or assortments of living life forms. Nor should they have the capacity
to hold licenses on organs, cells, qualities or proteins, whether actually happening,
hereditarily changed or generally modified.

This gathering likewise unequivocally contradicts government financing for the Human
Genome Diversity Project. Specifically, it is worried about social occasion tests of
human hereditary material from indigenous groups the world over. Related issues
incorporate responsibility for lines, educated assent before giving the example, protecting
of hereditary arrangements, and who ought to profit by the offer of related items.

Present issues that the public seems to be conscious about and the organizations
such as National Academy of Science's Institute of Medicine seem to take forward
are “Protection of the rights of the first pioneer patients”, “Prevention of the
introduction of dangerous animal pathogens into the human population”, “Finding
the idea of transplanting animal organs into humans acceptable”.

Creation of New Genomes

The science of developing transgenic animals is just beginning. Critics contend that it
raises both animal physiological (possible loss of function or generation of deformities)
or psychological problems (unacceptable levels of stress or loss of function) and
associated ethical issues.

Organ Transplants

Organ transplants and the availability of embryological tissue for research are important
and difficult issues for modern medicine. Many lives are prolonged or saved every year
through organ transplants. The National Organ Transplantation Act prohibits the sale of
human tissue and organs for transplantation. This prohibition does not apply to non-
transplantation purposes, including the sale of organs and other parts, such as
embryological tissue, for research.

Reframing Bioethical Issues – for the Public Policy needs

There are characteristic clashes required in how biotechnology creates as an industry and
the way moral inquiries and open arrangement positions are talked about and embraced.
Key components incorporate, for instance:

• How to characterize and assess man's fundamental long term relationships to his
hereditary legacy, different species and his biological framework;
• How to address the weight to rapidly advance logical research and to abuse new item
applications as they develop;
• What need to allow business needs to quickly realize an exceptional yield on an
extremely costly interest in a turbulent commercial center.

Issues are set inside clashing time skylines and esteem systems. Research and showcasing
time skylines are generally short, stressing quick monetary result and logical renown.
Interestingly, bioethics and open approach addresses frequently include a long haul time
skyline (eras of individuals), entire frameworks (biological or industry), and the nature of
individual and group life.
The meaning of what "safe" means and how to assess an adequate level of hazard is as yet
advancing. For instance, by what means ought to maker’s name bioengineered items and
different items that may utilize qualities embedded from plants to which individuals may
be hypersensitive? The vast scale accessibility of hereditary testing and its suggestions for
the work environment and for acquired medical issues will be issues that are seconds ago
being tended to.

There is solid focused weight to go ahead with new and possibly dangerous innovation in a
worldwide market. European, Asian and different countries are savagely contending with
each other to create and overwhelm a portion of the biotechnology business, if not the
business itself.